• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于L-岩藻糖或D-甘露糖的多价C-糖模拟物作为有效的DC-SIGN拮抗剂。

Polyvalent C-glycomimetics based on l-fucose or d-mannose as potent DC-SIGN antagonists.

作者信息

Bertolotti Benedetta, Sutkeviciute Ieva, Ambrosini Martino, Ribeiro-Viana Renato, Rojo Javier, Fieschi Franck, Dvořáková Hana, Kašáková Martina, Parkan Kamil, Hlaváčková Martina, Nováková Kateřina, Moravcová Jitka

机构信息

Department of Chemistry of Natural Compounds, University of Chemistry and Technology, Prague, Technická 5, 166 28 Prague, Czech Republic.

出版信息

Org Biomol Chem. 2017 May 10;15(18):3995-4004. doi: 10.1039/c7ob00322f.

DOI:10.1039/c7ob00322f
PMID:28443908
Abstract

The C-type lectin DC-SIGN expressed on immature dendritic cells is a promising target for antiviral drug development. Previously, we have demonstrated that mono- and divalent C-glycosides based on d-manno and l-fuco configurations are promising DC-SIGN ligands. Here, we described the convergent synthesis of C-glycoside dendrimers decorated with 4, 6, 9, and 12 α-l-fucopyranosyl units and with 9 and 12 α-d-mannopyranosyl units. Their affinity against DC-SIGN was assessed by surface plasmon resonance (SPR) assays. For comparison, parent O-glycosidic dendrimers were synthesized and tested, as well. A clear increase of both affinity and multivalency effect was observed for C-glycomimetics of both types (mannose and fucose). However, when dodecavalent C-glycosidic dendrimers were compared, there was no difference in affinity regarding the sugar unit (l-fuco, IC 17 μM; d-manno, IC 12 μM). For the rest of glycodendrimers with l-fucose or d-mannose attached by the O- or C-glycosidic linkage, C-glycosidic dendrimers were significantly more active. These results show that in addition to the expected physiological stability, the biological activity of C-glycoside mimetics is higher in comparison to the corresponding O-glycosides and therefore these glycomimetic multivalent systems represent potentially promising candidates for targeting DC-SIGN.

摘要

未成熟树突状细胞上表达的C型凝集素DC-SIGN是抗病毒药物开发的一个有前景的靶点。此前,我们已经证明基于d-甘露糖和l-岩藻糖构型的单价和二价C-糖苷是有前景的DC-SIGN配体。在此,我们描述了用4、6、9和12个α-l-呋喃岩藻糖基单元以及9和12个α-d-甘露糖基单元修饰的C-糖苷树枝状大分子的汇聚合成。通过表面等离子体共振(SPR)分析评估了它们对DC-SIGN的亲和力。为了进行比较,还合成并测试了母体O-糖苷树枝状大分子。对于两种类型(甘露糖和岩藻糖)的C-糖模拟物,均观察到亲和力和多价效应明显增加。然而,当比较十二价C-糖苷树枝状大分子时,就糖单元而言(l-岩藻糖,IC 17 μM;d-甘露糖,IC 12 μM),亲和力没有差异。对于其余通过O-或C-糖苷键连接l-岩藻糖或d-甘露糖的糖树枝状大分子,C-糖苷树枝状大分子的活性明显更高。这些结果表明,除了预期的生理稳定性外,C-糖苷模拟物的生物活性比相应的O-糖苷更高,因此这些糖模拟多价系统代表了靶向DC-SIGN的潜在有前景的候选物。

相似文献

1
Polyvalent C-glycomimetics based on l-fucose or d-mannose as potent DC-SIGN antagonists.基于L-岩藻糖或D-甘露糖的多价C-糖模拟物作为有效的DC-SIGN拮抗剂。
Org Biomol Chem. 2017 May 10;15(18):3995-4004. doi: 10.1039/c7ob00322f.
2
Nonhydrolyzable C-disaccharides, a new class of DC-SIGN ligands.不可水解的C-二糖,一类新型的DC-SIGN配体。
Carbohydr Res. 2016 Nov 29;435:7-18. doi: 10.1016/j.carres.2016.09.005. Epub 2016 Sep 9.
3
New lipophilic glycomimetic DC-SIGN ligands: Stereoselective synthesis and SPR-based binding inhibition assays.新型亲脂性糖基 mimic DC-SIGN 配体:立体选择性合成及基于 SPR 的结合抑制测定。
Bioorg Chem. 2021 Feb;107:104566. doi: 10.1016/j.bioorg.2020.104566. Epub 2020 Dec 19.
4
New branched amino acids for high affinity dendrimeric DC-SIGN ligands.新型支链氨基酸用于高亲和力树突状细胞特异性细胞间黏附分子-3 结合非整合素配体
Bioorg Med Chem. 2018 Mar 1;26(5):1006-1015. doi: 10.1016/j.bmc.2017.12.036. Epub 2017 Dec 26.
5
Monovalent mannose-based DC-SIGN antagonists: targeting the hydrophobic groove of the receptor.基于单糖甘露糖的DC-SIGN拮抗剂:靶向受体的疏水凹槽
Eur J Med Chem. 2014 Mar 21;75:308-26. doi: 10.1016/j.ejmech.2014.01.047. Epub 2014 Jan 31.
6
Second generation of fucose-based DC-SIGN ligands: affinity improvement and specificity versus Langerin.第二代岩藻糖基 DC-SIGN 配体:对 Langerin 的亲和力改善和特异性。
Org Biomol Chem. 2011 Aug 21;9(16):5778-86. doi: 10.1039/c1ob05573a. Epub 2011 Jul 7.
7
Pseudosaccharide functionalized dendrimers as potent inhibitors of DC-SIGN dependent Ebola pseudotyped viral infection.假寡糖功能化树枝状聚合物作为有效的 DC-SIGN 依赖的埃博拉假病毒感染抑制剂。
Bioconjug Chem. 2011 Jul 20;22(7):1354-65. doi: 10.1021/bc2000403. Epub 2011 Jun 20.
8
Designing nanomolar antagonists of DC-SIGN-mediated HIV infection: ligand presentation using molecular rods.设计DC-SIGN介导的HIV感染的纳摩尔级拮抗剂:使用分子棒进行配体展示。
Chem Commun (Camb). 2015 Mar 4;51(18):3816-9. doi: 10.1039/c4cc09709b.
9
Design, synthesis and activity evaluation of mannose-based DC-SIGN antagonists.基于甘露糖的 DC-SIGN 拮抗剂的设计、合成与活性评价。
Mol Divers. 2011 May;15(2):347-60. doi: 10.1007/s11030-010-9285-y. Epub 2010 Nov 14.
10
Unique DC-SIGN clustering activity of a small glycomimetic: A lesson for ligand design.一种小糖模拟物独特的 DC-SIGN 聚类活性:对配体设计的启示。
ACS Chem Biol. 2014 Jun 20;9(6):1377-85. doi: 10.1021/cb500054h. Epub 2014 May 6.

引用本文的文献

1
Molecular Recognition in C-Type Lectins: The Cases of DC-SIGN, Langerin, MGL, and L-Sectin.C 型凝集素中的分子识别:以 DC-SIGN、 langerin、MGL 和 L-选择素为例。
Chembiochem. 2020 Nov 2;21(21):2999-3025. doi: 10.1002/cbic.202000238. Epub 2020 Jul 2.
2
-Mannosyl Lysine for Solid Phase Assembly of Mannosylated Peptide Conjugate Cancer Vaccines.甘露酰赖氨酸用于甘露糖肽缀合物癌症疫苗的固相组装。
ACS Chem Biol. 2020 Mar 20;15(3):728-739. doi: 10.1021/acschembio.9b00987. Epub 2020 Feb 20.
3
Lectin PLL3, a Novel Monomeric Member of the Seven-Bladed β-Propeller Lectin Family.
凝集素 PLL3,七叶β-螺旋桨结构家族的新型单体成员。
Molecules. 2019 Dec 11;24(24):4540. doi: 10.3390/molecules24244540.
4
Glycans in drug discovery.药物研发中的聚糖
Medchemcomm. 2019 Jul 26;10(10):1678-1691. doi: 10.1039/c9md00292h. eCollection 2019 Oct 1.
5
Fucosylated inhibitors of recently identified bangle lectin from Photorhabdus asymbiotica.来自 Photorhabdus asymbiotica 的新发现的 bangle 凝集素的岩藻糖基抑制剂。
Sci Rep. 2019 Oct 17;9(1):14904. doi: 10.1038/s41598-019-51357-9.
6
Strategies for the Development of Glycomimetic Drug Candidates.糖模拟候选药物的开发策略。
Pharmaceuticals (Basel). 2019 Apr 11;12(2):55. doi: 10.3390/ph12020055.